Lesogaberan

Last updated
Lesogaberan
Lesogaberan.svg
Lesogaberan ball-and-stick model.png
Names
Preferred IUPAC name
[(2R)-3-Amino-2-fluoropropyl]phosphinic acid
Other names
AZD-3355
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.133.162 OOjs UI icon edit-ltr-progressive.svg
PubChem CID
UNII
  • InChI=1S/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1 X mark.svgN
    Key: LJNUIEQATDYXJH-GSVOUGTGSA-N X mark.svgN
  • InChI=1/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1
    Key: LJNUIEQATDYXJH-GSVOUGTGBQ
  • O=[PH](O)C[C@H](F)CN
Properties
C3H9FNO2P
Molar mass 141.082 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

Lesogaberan (AZD-3355) was [1] an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). [2] As a GABAB receptor agonist, [3] it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD. [4]

References

  1. ↑ AstraZeneca. "AZD3355". Archived from the original on 26 April 2012. Retrieved 30 December 2011.
  2. ↑ Bredenoord, Albert J. (2009). "Lesogaberan, a GABAB agonist for the potential treatment of gastroesophageal reflux disease". IDrugs. 12 (9): 576–584. PMID   19697277.
  3. ↑ Alstermark; Amin, K; Dinn, SR; et al. (2008). "Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors". Journal of Medicinal Chemistry. 51 (14): 4315–4320. doi:10.1021/jm701425k. PMID   18578471.
  4. ↑ Brian E. Lacy; Robert Chehade; Michael D. Crowell (2010). "Lesogaberan". Drugs of the Future. 35 (12): 987–992. doi:10.1358/dof.2010.035.012.1540661. S2CID   258021903.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.